Presented this week at the ECCMID annual meeting, the method uses mass spec to detect alterations to bacteria lipopolysaccharides that confer resistance.
The firm also announced a CE mark and pending commercial release for a FilmArray Respiratory Panel test for 22 pathogens responsible for respiratory tract infections.
Applied Biocode intends to have panel for identifying 18 gastrointestinal pathogens on the clinical market by the end of the year.
While point-of-care molecular testing of patients with respiratory illness wasn't associated with lower antibiotic use, patients tested had shorter drug courses.
Kits with the affected products may not be able to fully extract nucleic acids from samples and detect infection or provide a correct diagnosis.
Companies with diverse infectious disease diagnostic technology offerings said that molecular methods are complementary to, not competitive with traditional diagnostics.
FilmArray drove business growth in molecular biology, contributing €80 million to Q4 revenues and €249 million to FY 2016 revenues.
The firm's GI panel has also been recently evaluated in pediatric populations, demonstrating a marked increase in overall pathogen detection.
The report focused on identification of filamentous fungi and mycobacteria, and testing for resistance and susceptibility to antibiotics.
The analyses found solid evidence that MALDI-based clinical microbiology systems bettered patient care, but effects on hospital costs were less clear.
A fire at a Manchester hospital may have destroyed lab equipment and data, the Guardian reports.
Researchers generate a genetic database from skeletal remains from the 1845 Franklin Expedition to the Arctic, Live Science reports.
Researchers in China have begun another trial using CRISPR/Cas9 approaches in cancer patients, according to the Wall Street Journal.
In Science this week: human DNA found in sediments from archeological sites lacking bones, and more.